New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2013
14:45 EDTINCYIncyte presents final results from a Phase I trial of INCB024360
Incyte presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 IDO1, inhibitor, INCB024360, at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies. Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
08:55 EDTINCYIncyte price target raised to $125 from $115 at Leerink
Leerink raised its price target for Incyte to $125 saying its survey of 49 U.S. hematologists indicated Jakafi has blockbuster potential in polycythemia vera. The firm keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use